skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Treating Lennox–Gastaut syndrome in epileptic pediatric patients with third-generation rufinamide

Review

(1738) Views  (416) Full article downloads

Authors: Jessica Gresham, Lea S Eiland, Allison M Chung

Published Date September 2010 Volume 2010:6(1) Pages 639 - 645
DOI: http://dx.doi.org/10.2147/NDT.S6465

Jessica Gresham1, Lea S Eiland2,3, Allison M Chung2,4
1Auburn University, Harrison School of Pharmacy (AUHSOP), 2Department of Pharmacy Practice, AUHSOP, 3University of Alabama, School of Medicine, Huntsville Regional Medical Campus, 4University of South Alabama School of Medicine, Department of Pediatrics, Mobile, Alabama, USA

Abstract: Lennox–Gastaut syndrome (LGS) is a rare but debilitating pediatric epileptic encephalopathy characterized by multiple intractable seizure types. Treatment of LGS is challenging because of the small number of antiepileptic drugs (AEDs) which are effective for this syndrome, as well as the need for polytherapy in the majority of patients. This review focuses on the treatment of LGS with rufinamide, a recently approved third-generation AED with reported efficacy as adjunctive therapy for LGS. All relevant papers identified through a PubMed search on the treatment of LGS with rufinamide were reviewed. To date, the literature suggests improvements in seizure frequency for pediatric patients with LGS on rufinamide. Rufinamide appears to be especially effective for atonic or drop attack seizures. Rufinamide also displays a favorable adverse event profile compared with the older anticonvulsants, as well as a minimal number of drug interactions, making it a promising option for the adjunctive treatment of seizures associated with LGS.

Keywords: epilepsy, Lennox-Gastaut syndrome, pediatrics, seizure, rufinamide






Readers of this article also read:

Role of rufinamide in the management of Lennox-Gastaut syndrome (childhood epileptic encephalopathy)
Pupillography of automated swinging flashlight test in amblyopia
Treatment of Lennox-Gastaut syndrome: overview and recent findings
Update on the management of Lennox-Gastaut syndrome with a focus on rufinamide
Refinement of rigid-body protein–protein docking using backbone and side-chain minimization with a coarse-grained model
ABO and rhesus blood group distribution in Kurds
Improvement of social adaptation in depression with serotonin and norepinephrine reuptake inhibitors
Update on treatment of partial onset epilepsy: role of eslicarbazepine
Neighborhood socioeconomic disadvantage, individual wealth status and patterns of delivery care utilization in Nigeria: a multilevel discrete choice analysis
Clobazam as an adjunctive therapy in treating seizures associated with Lennox–Gastaut syndrome